Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed the day trading at $30.41 down -1.84% from the previous closing price of $30.98. In other words, the price has decreased by -$1.84 from its previous closing price. On the day, 0.52 million shares were traded. CRNX stock price reached its highest trading level at $31.2 during the session, while it also had its lowest trading level at $30.21.
Ratios:
For a better understanding of CRNX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.53 and its Current Ratio is at 22.53. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Neutral rating and assigned the stock a target price of $36.
On March 25, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $60.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 12 ’25 when Betz Stephen F. sold 97,483 shares for $32.23 per share. The transaction valued at 3,141,877 led to the insider holds 99,713 shares of the business.
STEPHEN BETZ bought 97,483 shares of CRNX for $3,151,625 on Jun 12 ’25. On Mar 19 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 2,515 shares for $34.20 each. As a result, the insider received 86,021 and left with 72,233 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 2848811776 and an Enterprise Value of 1625507712. For the stock, the TTM Price-to-Sale (P/S) ratio is 7913.37 while its Price-to-Book (P/B) ratio in mrq is 2.27. Its current Enterprise Value per Revenue stands at 2138.826 whereas that against EBITDA is -4.352.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.34, which has changed by -0.44058132 over the last 52 weeks, in comparison to a change of 0.16564083 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is -1.84%, while the 200-Day Moving Average is calculated to be -24.95%.
Shares Statistics:
Over the past 3-months, CRNX traded about 792.35K shares per day on average, while over the past 10 days, CRNX traded about 739130 shares per day. A total of 93.53M shares are outstanding, with a floating share count of 86.72M. Insiders hold about 7.43% of the company’s shares, while institutions hold 104.79% stake in the company. Shares short for CRNX as of 1751241600 were 10821713 with a Short Ratio of 13.66, compared to 1748563200 on 10210375. Therefore, it implies a Short% of Shares Outstanding of 10821713 and a Short% of Float of 13.149999000000001.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
